AN2 Therapeutics, Inc. (ANTX) vs Coherus Oncology, Inc. (CHRS)
A side-by-side comparison of AN2 Therapeutics, Inc. and Coherus Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANTX
AN2 Therapeutics, Inc.
$5.61HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CHRS
Coherus Oncology, Inc.
$1.12HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ANTX vs CHRS
growth of $100 · dividends reinvested · last 5yANTX -63.6% (-18.3%/yr)CHRS -91.3% (-38.7%/yr)ANTX compounded faster over this window
ANTX CHRS
ANTX vs CHRS: by the numbers
- •ANTX is the larger company ($202M vs $173M market cap).
- •Both run net losses; ANTX's is the smaller (0.00% vs -257.10% net margin).
Metrics side by side
Valuation
| Metric | ANTX | CHRS |
|---|---|---|
| P/S ratio | N/A | 3.40 |
| P/B ratio | 2.66 | 2.84 |
Profitability
| Metric | ANTX | CHRS |
|---|---|---|
| Gross margin | 0.00% | 63.55% |
| Operating margin | 0.00% | -425.72% |
| Net margin | 0.00% | -257.10% |
| ROE | -47.78% | -215.26% |
| ROIC | -51.01% | -135.38% |
Growth (annualized)
| Metric | ANTX | CHRS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -33.60% |
| Total return CAGR (5Y) | N/A | -41.38% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.